Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Mahesh Iddawela MBBS,FRACP, PhD (Cantab)
Consultant Medical Oncologist , LaTrobe Regional Hospital
Department of Anatomy & Developmental Biology
Biomedicine Discovery Institute
Monash University
Clayton.
Breast and Prostate Cancer
Management and Survivorship
Breast Cancer Survival
Survival rates are better in Australia
than most other countries in the world
In the last 25 years
the risk of dying
from breast cancer
has fallen by 2%
every year
Incidence has steadied while
mortality continues to fall
Source: Australian Institute of Health and Welfare & National Breast Cancer Centre 2009. Breast cancer in Australia: an overview, 2009.
Early breast cancer
• Breast cancer confined to the breast and
nearby lymph nodes
• Aim of treatment is cure
Secondary breast cancer
(metastatic, advanced, stage 4)
• Cancer that has spread
beyond the breast and
lymph nodes to other
more distant parts of the
body
• Incurable, but ….
• Chronic illness– Some women survive for
many years
Diagnosis and next steps
• Biopsy of abnormal area– confirm if it’s cancer
– May include a biopsy of lymph nodes
• Appointment with a surgeon to discuss– when to remove the tumour
– what surgery is needed for the axillary nodes
• Pathology– report on the tumour
Local treatment: Surgery
• Surgical options– Breast conserving (lumpectomy)
– Mastectomy, with or without reconstruction
Local treatment: Axillary surgery
• Sentinel node biopsy– No signs of lymph node involvement
• Axillary clearance– Known LN involvement
– Following positive SNB
After surgery, the pathology report
tells us…
…about the tumour
•How big is it– Size in mm
•Did the surgery clear it?– Margins
•Has it spread to the lymph nodes?– Number involved
•Is it growing slowly or quickly?– Grade (1,2,3)
…and what is making it grow
•Is it driven by hormones– Oestrogen receptors
– Progesterone receptors
•Is it driven by overactivity of
HER2?– HER2 normal (negative)
– HER2 increased (positive)
•Is something else driving the
growth?– Triple negative
Further treatment decisions take this information, plus a woman’s
age and other medical conditions, into account.
Local Treatment: Radiotherapy
• Usually given to breast area after breast
conserving surgery (lumpectomy)
• May need to be given after mastectomy
Systemic (adjuvant) treatment
Controlling microscopic breast cancer cell growth locally or around the body.
Aim is to increase the chance of overall survival by reducing the risk of recurrence of breast cancer without increasing the risk of significant other illnesses.
Systemic treatments may involve a combination of:• chemotherapy• hormone (endocrine) therapy (e.g. tamoxifen)• targeted therapy (e.g. Herceptin)
Paradigm shift in the way breast cancer is viewed
Hormone blocking therapies
• Tamoxifen– blocks oestrogen receptor cells so that
oestrogen can’t get into the cancer cells
and stimulate their growth
– used in pre and post menopausal women
• Aromatase inhibitors (Arimidex,
Femara, Aromasin)– reduce the amount of oestrogen produced
in the body so it is not able to ‘feed’ cancer
cells
– used in post-menopausal women only
Breast cancer recurrence and
hormone therapy
26.5%
38.3%
15.1%
24.7%
0
10
20
30
40
50
0 5 10 15
Pe
rce
nta
ge
of
wo
me
n w
ho
ex
pe
rie
nce
a r
ecu
rre
nce
Years
Women who did not take hormone therapy
Women who did take hormone therapy for five yearsafter diagnosis
Side effects of hormone therapy
• Hot flushes
• Interference with sleep
• Mood changes
• Joint stiffness
• Joint pain (arthralgia)
• Decreased sex drive
• Vaginal symptoms
• Thinning hair and nails
Can be short and long term
Herceptin reduces recurrence in HER2+
early breast cancer by about half (2006)
87% 85%
Early breast cancer
%
US trials: disease free survival
... and improves survival for women with secondary disease
Triple negative breast cancer
• Around 15% of breast cancers
• Often associated with BRCA1 gene
mutation
• No receptors to target
• Chemotherapy very effective
• Research into new treatments– PARP inhibitors
– Antiangiongenic agents
– Epidermal growth factor receptors (EGFR)
How common or Incidence
6/29/2018 (18)
• Australia - 19400 cases and 3800 deaths
• Victoria - 4500 new cases and 850 deaths
• Gippsland- 258 cases and 57 deaths
6/29/2018 (19)
What to do when first line
Docetaxel treatment fails?
VS.
In 2011 the choices were limited
Palliative Chemotherapy
Phase I study
Beach
Targeting the Androgen Pathway
• Androgen Biosynthesis Inhibitors– *Abiraterone Acetate
– TAK 700
– VN/124-1 (TOK-001)
• Novel Anti-Androgens– *Enzalutamide (MDV3100)
– RD 162
– EPI-001 (AR N-Terminal)
– SNARE-1 (selective nuclear receptor exporter-1)
* FDA approved
De Bono et al. NEJM
2011
14.8 vs. 10.9 <0.05
COU-AA- 301 Study Abiraterone vs.placebo
AFFIRM study
• 18.4 vs. 13.6 months
months
13.6
• Scher et al. NEJM
2012
23ASCO June 2012
Early Chemotherapy in Metastatic
Prostate cancer
• CHAARTED and STAMEDE showed a
benefit to early chemotherapy.
• This has changed the management of
prostate cancer.
• Work being done to understand the role of
subgroups in the studies.
Sweeney et al, NEJM 2015
57 vs 44 months
13 months
OS Benefit in Recent CRPC Trials
Trial/Agent
Mechanism ComparatorSurvival
(months)Hazard Ratio
P-value
AFFIRMEnzalutamide
2012
Androgen Receptor Signaling Inhibitor
Placebo 18.4 vs. 13.6 0.631 <0.0001
COU-AA-301 Abiraterone +
prednisone 2011
CYP17 InhibitorPlacebo +prednisone
14.8 vs. 10.9 0.646 <0.0001
TROPIC Cabazitaxel +
prednisone2010
CytotoxicMitoxantrone +
prednisone15.1 vs. 12.7 0.70 <0.0001
Alpharadin*2012
Alpha-particle emitting
radionuclidePlacebo 14.9 vs. 11.3 0.69 0.0018
* Only 60% of these patients were post-docetaxel patients
De Bono et al. ASCO 2012
Blood tests and outcome in prostate cancer- Trial
lead by Gippsland Oncology
• Patients treated with chemotherapy or hormonal
therapy get blood tests to evaluate circulatory DNA
and mRNA.
• Outcome correlated with the response to treatment.
• Thus far 35 patients have been recruited.
• Collaboration between Prostate Cancer Research
Group at Monash, Latrobe Regional Hospital,
Eastern Health, Charles Gardner and Edith Cowan
University.
PI- Mahesh Iddawela
Response to treatment and AR copy /ARV-7 status
• 2 out of 3 patients had poor response to hormonal therapy, if both AR and ARV-7 are altered.
• AR gained but ARV-7 negative samples had a better response to AR targeting (> 50% PSA decline).
• Some patients are genomically neutral with no AR/ARV-7 changes.-100
-80
-60
-40
-20
0
20
40
60
80
100
120
LRH03 LRH04 LRH05 LRH08 LRH09 LRH10 LRH11
% P
SA
resp
on
se
Waterfall plot of PSA Response
Red- both AR and ARV-7 altered
Blue- AR gain, AR normal and no ARV-7
• Long-term
- Cardiovascular Risks
- Increasing weight
- Diabetes
- Osteoporosis
- Psycological issues
6/29/2018 (29)
Gippsland Cancer Survivorship Program
Eli Ristevski, Taryn Robinson, Jeannette Douglas, Danielle Roscoe, Michelle Pryce, Trisha Wright
Mahesh Iddawela
Gippsland Cancer Care CentreLatrobe Regional Hospital
In collaboration with:
Challenges of Cancer Survivorship
• Survivors are at risk for a wide range of late
physical effects of their primary treatment
• Compared with others, cancer survivors have a
substantially increased burden of illness:
– Days lost from work, inability to work
– General health perception
– Need help with daily activities
Ganz PA. J Clin Oncol. 2006;24:5105-5111. American Society of Clinical Oncology. Cancer Advances Information
From the Experts: Cancer Survivorship – Increasing Survival, Improving Lives. December 2004.
Participants
Cancer survivors
- 18 years
- low risk
Carers
- Self identify as carer
Clinicians & Services
- Oncology specialists &
Nurses
- GPs
- Service Managers
Breast
Prostate
Colon
Lymphoma
Oncological Emergencies
• Complications of the cancer (treatment)
Spinal cord compression – cancers which spread to bone (BLKTP), myeloma, primary bone tumours (Ewings, osteosarcoma), bone lymphoma
Superior vena caval obstruction – SVCO –mediastinal tumours (lung cancer, lymphomas, germ cell tumours, thyroid, lung cancer)
Oncological Emergencies
Complications of the cancer (treatment)
Hypercalcaemia – BLKTP, myeloma, paraneoplastic –lung cancer
Acute renal failure – ureteric obstruction (gynae masses), prostatic obstruction (prostate cancer, sarcoma), n.sepsis, hypercalcaemia, myeloma
Intestinal perforation – ovarian cancer, bowel cancer,
+ avastin
Oncological Emergencies
Complications of treatment (cancer)
neutropenic sepsis (chemotherapy)bowel perforation (chemotherapy, avastin)bleeding / thrombosis (chemotherapy,
avastin)congestive heart failure (anthracyclines,
Herceptin, sunitinib)acute renal failure (high dose methotrexate,
neutropenic sepsis, platinum, ifosfamide)
Overview
1. Neutropenic sepsis
2. Spinal cord compression
3. Hypercalcaemia
Neutropenic sepsis
• Kills !!!!
• Rate of death 1% of among adjuvant breast cancer patients.
• Can be avoidable
• National agenda Sepsis management to reduce deaths.
• Treatment within 1 HOUR
Neutropenic sepsis
Definition• Fever > 38.5° or 38 ° 1hr apartwithNeutrophil<1.0 or predicted to decrease
-Unwell with no temperature-Patients on corticosteroids-Hypotension/Hypothermia
• Gram negative cover important- severe infections-infections in sites outside blood (urine, biliary, skin and
respiratory)
• Anaerobes unlikely (3.4%)-mucositis, diarrhoea, necrotising neutropenic colitis
Spinal cord compression
• Risk cord compression in the five years before death was 2.5% (0.2-7.9%)1.
• Autopsy studies suggested that 5 percent of patients dying with cancer have SCC.
• Vertebral metastasis at autopsy in 90% of prostate, 74% of breast and 45% of lung.
1Clin Oncol (R Coll Radiol) 2003 Jun;15(4):211-7
Epidemiology
Patients with known malignancy
Common malignancies1-
Prostate (19%), non-small cell lung (18%)
and breast (15%), Kidney (10%)
Others- NHL, plasmacytoma, MM.
Patients with unknown malignancy
Lung cancer, CUP, MM, NHL make up 78%
Acta Neurochir (Wien) 1990;107(1-2):37-43.
Pathophysiology
Thecal sac compression
and 85-90% due metastatic
tumour in the vertebral
bodies.
10% due to paraspinal
mass (esp. lymphoma)
Encircle thecal sac
vasogenic oedema
& infarction
•
Diagnosis
• Clinical features• Early recognition of features is essential for best
management.• Pain (83-95%)-preceeds neurology 7 wks.
-lumbosacral-radicular-thoracic-bandlike
• Motor (60-85%) -weakness pyramidal-cauda equina-weakness and reduced deep reflexes-increasing weakness and gait problems
Sensory (less common)-ascending numbness
-sensory level 1-5 dermatomes below compression.
Bladder/bowel dysfunction- late finding.
-autonomic neuropathy with retention can be sole
symptom
Ataxia- in cancer patients raise suspicion.
Investigations
• MRI –WHOLE SPINE-21% cases missed if only thoracic or lumbosacral imaged.
• CT Myelography- if MRI CI
D.Dx
• SCC
• Malignant disease-vertebral metastasis only-Leptomeningeal metastasis (coexist with headache, cranial nerve
palsies)-malignant plexopathy- involving any of the peripheral nerve plexus.
-radicular pain-Brachial-lung, breast
-Radiation myelopathy- past radiation, 12-15 months,UMN and numbness
Management
• Dexamethasone 8mg BD.-improve the pain and neurology
• PPI• Thromboprophylaxis• Laxatives• Consider neurosurgery
-solitary lesion-good performance status-stage of systemic disease